News | June 15, 2022
Eurocine Vaccines expands portfolio with a therapeutic HSV-2 vaccine candidate
Redbiotec has a right to royalties on Eurocine Vaccines´ net sales of an approved HSV-2 vaccine, should such sales arise.
Redbiotec has a right to royalties on Eurocine Vaccines´ net sales of an approved HSV-2 vaccine, should such sales arise.
TAK-003 is currently undergoing regulatory review for potential licensure in both the European Union
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
Formula attenuates 99% of 365 coronaviruses in computer models
Both mRNA-1020 and mRNA-1030 target hemagglutinin and neuraminidase antigens, two major influenza surface glycoproteins that are essential across the viral life cycle
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
The FDA decision is primarily informed by the positive results of a proof-of-concept, Phase 2a study evaluating the safety, immunogenicity, and efficacy of a single dose of 120µg RSVpreF in a human viral challenge model in healthy adults 18 to 50 years of age
Data to establish the safety profile and human dose of vaccine candidate
Blood contains a mixture of exosomes secreted from nearly all tissues and cells, and exosomes from other tissues can mask changes caused by disease, making it difficult to detect the presence of biomarkers that reflect disease
This decision does not impact the ongoing AReSVi 006 phase III trial for RSV older adults.
Subscribe To Our Newsletter & Stay Updated
